Oral bioavailability and pharmacokinetics of DRF-4367, a new cox-2 inhibitor in rats
@article{Ramesh2010OralBA, title={Oral bioavailability and pharmacokinetics of DRF-4367, a new cox-2 inhibitor in rats}, author={M. Ramesh and R. Mamidi and Kota Jagannath and S. K. Singh and K. S. Rao and Y. K. Rao and Casturi Seshagirirao and R. Rajagopalan and N. Srinivas}, journal={European Journal of Drug Metabolism and Pharmacokinetics}, year={2010}, volume={28}, pages={137-141} }
SummaryThe pharmacokinetic characterization of DRF-4367 (a new diaryl pyrazole derivative), a potent selective COX-2 inhibitor was performed in Wistar rats. In the first study, a single dose of 2, 5, 10, 30 or 100 mg/kg DRF-4367 was given orally to rats for investigating the dose proportionality and/or linearity in the pharmacokinetics. In the second study, a single intravenous bolus dose of DRF-4367 was given at a dose of 10 mg/kg to calculate the absolute oral bioavailability, clearance and… CONTINUE READING
One Citation
Glucuronidation of DRF-6574, hydroxy metabolite of DRF-4367 (a novel COX-2 inhibitor) by pooled human liver, intestinal microsomes and recombinant human UDP-glucuronosyltransferases (UGT): Role of UGT1A1,1A3 and 1A8
- Biology, Medicine
- European Journal of Drug Metabolism and Pharmacokinetics
- 2010
- 3
References
SHOWING 1-9 OF 9 REFERENCES
Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats
- Medicine, Chemistry
- Biopharmaceutics & drug disposition
- 2002
- 28
Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents.
- Medicine
- Current drug targets
- 2001
- 72
Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.
- Medicine
- Proceedings of the National Academy of Sciences of the United States of America
- 1994
- 1,454
- PDF
Cyclooxygenase inhibitors--current status and future prospects.
- Chemistry, Medicine
- European journal of medicinal chemistry
- 2001
- 583
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
- Medicine
- The New England journal of medicine
- 2000
- 2,411
Design, Synthesis and Biological Evaluation of 2Substituted Benzene sulphonamide Containing Novel Classof 1,5-Diaryl Pyrazoles as Cyclooxy -genase-2 Inhibitors
- J. Med. Chern. submitted
- 2002
The effect of celecoxib, acyclooxygenase-2 inhibitor, in familial adenomatous polyposis
- New Eng J Med
- 2000